Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-ART medical cannabis add-on study in rheumatoid arthritis and ankylosing spondylitis
2017-004226-15Phase 2Completed
- Sponsor
- King Christian X's Rheumatism Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cannabidiol and dronabinol in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) (2 arms), sponsored by King Christian X's Rheumatism Hospital. Primary endpoint: Pain visual analog scale response. Started Jan 2018; status: completed.
02
Drugs
cannabidioldronabinol
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2017-004226-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004226-15.